559. Deputy Billy Kelleher asked the Minister for Health his views that the new medicines pricing agreement will lead to cost savings in respect of existing biologic, high-technology medicines, given that a lower reimbursement price for biologics will not be possible due to an inability for biosimilars to enter the market; the reason for introducing a clause into the agreement which links the reimbursement price of biologics to the biosimilars entering the market; and if he will make a statement on the matter. [21015/16]

Summary

559. Deputy Billy Kelleher asked the Minister for Health his views that the new medicines pricing agreement will lead to cost savings in respect of existing biologic, high-technology medicines, given that a lower reimbursement price for biologics will not be possible due to an inability for biosimilars to enter the market; the reason for introducing a clause into the agreement which links the reimbursement price of biologics to the biosimilars entering the market; and if he will make a statement on the matter. [21015/16]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Prices

  xml · EN · 12 July 2016

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.